Intellectual Product – Page 37

Regeneron Antitrust Suit Against Novartis Gains Momentum with Appellate Ruling

1 year ago talkbio0Tagged Antitrust, Appeal court backing, Eye treatments, Eylea & Lucentis, Legal patent, Novartis, Regeneron

Regeneron, Novartis, Antitrust lawsuit, Appeal court backing, Eye treatments (Eylea & Lucentis), Patent dispute

FDA Unexpectedly Postpones Approval Decision for Eli Lilly’s Donanemab, Schedules AdComm Review

1 year ago talkbio0Tagged Accelerated Approval, Aduhelm, Anticipated, Approved, aspects of adverse effects, Central Nervous System Agents, Cerebral Edema, Clinical Trials, Deferred, Donanemab, Effectiveness, eli lilly, Full approval, Hemorrhage, Leqembi, PCNS, Peripheral, precedent, Review [Publication Type], Safety, United States Food and Drug Administration

Donanemab, Eli Lilly, FDA delay, Approval postponement, Peripheral and Central Nervous System Drugs Advisory Committee (PCNS), Safety and efficacy review, Clinical trial results, Brain swelling and bleeding side effects, Accelerated approval declined, Leqembi and Aduhelm precedent, Full approval anticipated, Accelerated approval rejected.

Biden Ramps Up Fight Against High Drug Prices in State of the Union Address

1 year ago talkbio0Tagged Addresses (publication format), Biden administration, Big Pharma, Commercial Drug Sales, drug price, Generic Drug Cost-Sharing Limit, Cell & Gene Therapy, Inflation Reduction Act, Medicare Drug Negotiations, Out-of-Pocket Cap Expansion, Private insurance, Protections, Study models, Union

State of the Union Address, Biden Administration, Big Pharma, Drug Prices, Inflation Reduction Act, Medicare Drug Negotiations, Out-of-Pocket Cap Expansion, Private Insurance Protections, Generic Drug Cost-Sharing Limit, Cell & Gene Therapy Access Model, Commercial Drug Sales Rebates

Boundless Bio Joins 2024 IPO Surge Amidst Prominent Oncology Trial Outcomes

1 year ago talkbio0Tagged Bio, Boundless, Cancer-focused biotech, Clinical Data, IPO, Oncology trials, Public Offering, rally

Boundless Bio, Initial Public Offering (IPO), Cancer-focused biotech, 2024 IPO rally, Oncology trials, Clinical data readouts

Sionna Secures $182M Series C Funding to Advance Novel Cystic Fibrosis Treatment Pipeline

1 year ago talkbio0Tagged Citation, Cystic, Cystic Cystic fibrosis, Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, ICL4 inhibitor, NBD1, Sionna, Stabilizer - function

NBD1 stabilizers, ICL4 inhibitor, Cystic fibrosis, CFTR, NBD1, Cystic fibrosis, Cystic fibrosis, Sionna, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic Cystic fibrosis, Cystic fibrosis, Cystic Cystic, Cystic Cystic Cystic:, Search for the citation:

Gritstone Bio Implements Workforce Reduction Following Delay in COVID-19 Vaccine Trial

1 year ago talkbio0Tagged 40%, BARDA, Colorectal cancer vaccine, Contract agreement, COVID-19 vaccine trial, Gritstone Bio, Manufacturing delay, Missed funding, Project NextGen, workforce layoffs

Gritstone Bio, COVID-19 vaccine trial delay, 40% workforce layoffs, Phase 2b CORAL trial, Manufacturing delay, Missed funding, Project NextGen, BARDA contract, Colorectal cancer vaccine